Traws Pharma Sets 3Q 2026 Resubmission to MHRA for Phase 2a Influenza Study
TRAW•Traws Pharma will resubmit an updated toxicology data package for tivoxavir marboxil to the UK MHRA in 3Q 2026 to support a Phase 2a human influenza Challenge study. The company anticipates an MHRA decision within 30 days post-resubmission and plans to profile additional antiviral candidates for influenza treatment.
1. Updated Toxicology Data Submission
Traws Pharma is developing an updated toxicology data package for tivoxavir marboxil in response to detailed MHRA requirements to support its planned Phase 2a human influenza Challenge study. The company expects to resubmit the package in Q3 2026 and to receive a formal MHRA decision within 30 days of resubmission.
2. Antiviral Pipeline Expansion
Following MHRA feedback, Traws will initiate profiling of additional oral antiviral candidates targeting seasonal influenza, leveraging tivoxavir marboxil’s broad in vitro efficacy across multiple strains and its favorable pharmacokinetic profile for chemoprophylaxis.
3. Public Health Context
Seasonal influenza poses significant risks to elderly and immunocompromised populations, and Traws aims to address this need through an oral prophylaxis approach, which could reshape prevention strategies for high-risk groups if clinical proof of concept is achieved.
